Insider · CIK 0001492647

Almenoff June Sherie

Reports to the SEC for 7 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001492647

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-02	ATNMActinium Pharmaceuticals, Inc.A Award	Director	AAward	+18K sh	—	—	18,000
2026-09-02	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27K sh	—	—	27,000
2026-01-09	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2025-11-18	TENXTENAX THERAPEUTICS, INC.P Purchase	Director	PPurchase	+1,900 sh	$7.52	+$14.3K	1,993
2025-11-18	TENXTENAX THERAPEUTICS, INC.P Purchase	Director	PPurchase	+1,900 sh	$7.52	+$14.3K	1,993
2025-11-17	TENXTENAX THERAPEUTICS, INC.P Purchase	Director	PPurchase	+93 sh	$7.15	+$664.95	93
2025-11-17	TENXTENAX THERAPEUTICS, INC.P Purchase	Director	PPurchase	+93 sh	$7.15	+$664.95	93
2025-07-01	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+80K sh	—	—	80,000
2025-06-17	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.1K sh	—	—	20,100
2025-03-31	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−50K sh	—	—	0
2025-03-28	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,167 sh	—	—	3,167
2025-03-28	AVTXAvalo Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,167 sh	—	—	6,333
2024-12-10	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+100K sh	—	—	100,000
2024-11-13	AVTXAvalo Therapeutics, Inc.P Purchase	Director	PPurchase	+500 sh	$13.00	+$6,500	1,000
2024-11-12	AVTXAvalo Therapeutics, Inc.P Purchase	Director	PPurchase	+500 sh	$12.50	+$6,249.5	500
2024-11-01	ATNMActinium Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-08-13	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+24.6K sh	—	—	24,600
2024-08-13	AVTXAvalo Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+9,500 sh	—	—	9,500
2023-12-20	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,334 sh	—	—	3,334
2023-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+4,575 sh	—	—	4,575
2023-03-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,167 sh	—	—	1,167
2022-12-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+410 sh	—	—	410
2022-09-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+605 sh	—	—	605
2022-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+4,338 sh	—	—	4,338
2022-06-14	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2022-06-09	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2022-03-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+2,985 sh	—	—	2,985
2021-12-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+737 sh	—	—	737
2021-12-15	BCLIBRAINSTORM CELL THERAPEUTICS INC.A Award	Director	AAward	+2,000 sh	—	—	6,000
2021-12-10	BCLIBRAINSTORM CELL THERAPEUTICS INC.A Award	Director	AAward	+2,000 sh	—	—	4,000
2021-11-10	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2021-06-10	TENXTENAX THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+6,250 sh	—	—	6,250
2019-12-12	BCLIBRAINSTORM CELL THERAPEUTICS INC.A Award	Director	AAward	+2,000 sh	—	—	2,000
2019-01-04	BCLIBRAINSTORM CELL THERAPEUTICS INC.P Purchase	Director	PPurchase	+1,475 sh	$3.39	+$5,000.25	7,175
2018-08-27	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+253 sh	$4.96	+$1,254.88	800
2018-08-27	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+100 sh	$4.94	+$494	900
2018-08-27	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+47 sh	$4.90	+$230.3	547
2018-08-24	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+100 sh	$4.85	+$485	100
2018-08-24	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+400 sh	$4.99	+$1,996	500
2018-08-24	9 METERS BIOPHARMA, INC.P Purchase	COO and Chief Medical Officer	PPurchase	+500 sh	$4.85	+$2,425	1,400
2018-03-15	BCLIBRAINSTORM CELL THERAPEUTICS INC.A Award	Director	AAward	+5,700 sh	$3.50	+$20K	5,700
2018-03-15	BCLIBRAINSTORM CELL THERAPEUTICS INC.P Purchase	Director	PPurchase	+5,700 sh	$3.50	+$20K	5,700
2017-10-16	NeuBase Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+170K sh	—	—	170,000
2016-01-07	NeuBase Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+60K sh	—	—	60,000
2015-03-10	NeuBase Therapeutics, Inc.OptionA Award	Director	AAward	+84K sh	—	—	84,000
2015-02-06	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+6,000 sh	$6.75	+$40.5K	16,900
2014-09-03	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+1,200 sh	$8.05	+$9,660	127,566
2014-09-02	NeuBase Therapeutics, Inc.P Purchase	Director	PPurchase	+1,000 sh	$8.12	+$8,120	126,366
2014-07-02	Furiex Pharmaceuticals, Inc.D Disposition to Issuer	Director, President	DDisposition to Issuer	−24.6K sh	—	—	0
2014-07-02	Furiex Pharmaceuticals, Inc.Stock Options (to buy)D Disposition to Issuer	Director, President	DDisposition to Issuer	−83K sh	—	—	0

Recent filings

Accepted (ET)
Sep 44
Almenoff June Sherie0001213900-26-097742
SEC(opens sec.gov)
Jan 134
Almenoff June Sherie0001492647-26-000001
SEC(opens sec.gov)
Nov 204/A
Almenoff June Sherie0001492647-25-000004
SEC(opens sec.gov)
Nov 194
Almenoff June Sherie0001492647-25-000003
SEC(opens sec.gov)
Jul 34
Almenoff June Sherie0001654954-25-007739
SEC(opens sec.gov)
Jun 184
Almenoff June Sherie0001578563-25-000319
SEC(opens sec.gov)
Apr 24
Almenoff June Sherie0001213900-25-028230
SEC(opens sec.gov)
Apr 14
Almenoff June Sherie0001578563-25-000199
SEC(opens sec.gov)
Dec 124
Almenoff June Sherie0001654954-24-015471
SEC(opens sec.gov)
Nov 144
Almenoff June Sherie0001578563-24-000441
SEC(opens sec.gov)
Nov 54
Almenoff June Sherie0001213900-24-094632
SEC(opens sec.gov)
Aug 144
Almenoff June Sherie0001578563-24-000368
SEC(opens sec.gov)
Dec 214
Almenoff June Sherie0001628280-23-042492
SEC(opens sec.gov)
Jul 54
Almenoff June Sherie0001628280-23-024230
SEC(opens sec.gov)

Companies

Address

C/O ACTINIUM PHARMACEUTICALS, INC. 100 PARK AVE., 23RD FLOOR

NEW YORK, NY, 10017